When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. James P. Allison - Wikipedia

    en.wikipedia.org/wiki/James_P._Allison

    [21] [22] In the early 1990s, James Allison showed that CTLA-4 acts as an inhibitory molecule to restrict T-cell responses. In 1996, Allison was the first to show that antibody blockade of a T-cell inhibitory molecule (known as CTLA-4) could lead to enhanced anti-tumor immune responses and tumor rejection.

  3. Cytotoxic T-lymphocyte associated protein 4 - Wikipedia

    en.wikipedia.org/wiki/Cytotoxic_T-lymphocyte...

    CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA-4 binds CD80 and CD86 with ...

  4. Immune checkpoint - Wikipedia

    en.wikipedia.org/wiki/Immune_checkpoint

    Cancer Therapy by Inhibition of Negative Immune Regulation (CTLA4, PD1) A2AR & A2BR: The Adenosine A2A receptor is regarded as an important checkpoint in cancer therapy because adenosine in the immune microenvironment, leading to the activation of the A2a receptor, is negative immune feedback loop and the tumor microenvironment has relatively high concentrations of adenosine. [27]

  5. Checkpoint inhibitor - Wikipedia

    en.wikipedia.org/wiki/Checkpoint_inhibitor

    These are most likely due to the breadth of the induced T-cell activation when anti-CTLA-4 antibodies are administered by injection in the blood stream. Using a mouse model of bladder cancer, researchers have found that a local injection of a low dose anti-CTLA-4 in the tumour area had the same tumour inhibiting capacity as when the antibody ...

  6. Chemoimmunotherapy - Wikipedia

    en.wikipedia.org/wiki/Chemoimmunotherapy

    James Allison, now at the University of Texas MD Anderson Cancer Center, was an early pioneer of immunotherapy. He discovered that CTLA-4 inhibits T cells from fully attacking, and hypothesized that blocking CTLA-4 could unleash the immune system to fight cancer. Initially, his idea was met with skepticism, but he continued his research and ...

  7. Ipilimumab - Wikipedia

    en.wikipedia.org/wiki/Ipilimumab

    Bluestone's lab published studies, one together with Krummel and Allison, for in vitro studies of CTLA-4 function. [78] [79] In collaboration with Mark Jenkins, they were able to see effects of anti-CTLA-4 antibodies in vivo in an immunization setting, [80] but did not effectively carry this into tumor biology. Linsley and colleagues had made ...

  8. Timeline of immunology - Wikipedia

    en.wikipedia.org/wiki/Timeline_of_immunology

    1995 – James P. Allison is the first to describe the function of the critical immune checkpoint CTLA-4; 1995 – Regulatory T cells (Shimon Sakaguchi) 1995 – First Dendritic cell vaccine trial reported by Mukherji et al. 1995 – Discovery of the insect Imd NF-κB pathway [18]

  9. CTLA-4 - Wikipedia

    en.wikipedia.org/?title=CTLA-4&redirect=no

    What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code